Učitavanje...
ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
ALK positive non-small cell lung cancer is highly responsive to ALK inhibitors such as crizotinib, but drug resistance typically develops within a year of treatment. In this study we investigated whether IGF-1R is an independent druggable target in ALK-positive lung cancer cells. We confirmed that c...
Spremljeno u:
| Izdano u: | Sci Rep |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5654778/ https://ncbi.nlm.nih.gov/pubmed/29066738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-14289-w |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|